Locally advanced gastrointestinal cancers: moving forward in the neoadjuvant setting
Recent results from research have changed the treatment paradigm for some digestive tumours, but further evidence is needed to finetune the neoadjuvant approach
When to perform next-generation sequencing test in patients with cancer? ESMO updates its recommendations
NGS testing is now recommended also for patients with some rare tumours and to detect tumour-agnostic alterations
Atezolizumab plus sacituzumab govitecan show encouraging activity in inoperable triple-negative breast cancer
Efficacy and safety of the first-line novel combination were assessed in patients with untreated PD-L1 positive locally advanced or metastatic tumours
Triplet therapy shows promise in patients with ER positive/HER2 negative metastatic breast cancer
A synergic effect of olaparib, durvalumab and fulvestrant was observed across different mutated subgroups, with higher benefits in BRCA 1 and 2 carriers
Novel scenarios in targeting HR-positive/HER2-negative breast cancer
Studies provide evidence of potential efficacy for a novel CDK4-selective inhibitor and long-lasting benefits for a pan-AKT inhibitor
Sexual health in breast cancer: updated data from pharmacological and non-pharmacological interventions
Two studies provide new insights on the effects of vaginal oestrogen therapy and physical exercise to tackle sexual impairment
Pregnancy after breast cancer: study provides reassurance to BRCA carriers undergoing assisted reproductive techniques
No difference in risk recurrence or pregnancy outcomes was reported between young women with BRCA1 or BRCA2 mutations conceiving naturally and those using fertility treatments
Good tolerability of datopotamab deruxtecan supports its place in the treatment of HR+/HER2− breast cancer
In the TROPION-Breast01 trial, adverse events of special interest were generally low grade, easily managed and did not compromise scheduled treatment
Breast cancer research: lessons learnt from the past will shape the future
In her key lecture, the 2024 ESMO Breast Cancer Awardee Prof. Hope S. Rugo reflects on the current challenges in the field
Atezolizumab does not improve prognosis in early relapsing advanced triple-negative breast cancer
However, a higher objective response rate with atezolizumab was reported in the IMpassion132 trial suggesting that at least some patients could benefit from it